BioCardia (BCDA) has regained compliance with Nasdaq Capital Market listing standards. On October 1, 2025, Nasdaq confirmed the company meets Listing Rule 5550(b)(1), allowing BCDA to remain listed. This follows BioCardia’s efforts to strengthen its financial position and secure funding to support its therapeutic development and approved products.
問題なく前へ🍵
BioCardia (BCDA) has regained compliance with Nasdaq Capital Market listing standards. On October 1, 2025, Nasdaq confirmed the company meets Listing Rule 5550(b)(1), allowing BCDA to remain listed. This follows BioCardia’s efforts to strengthen its financial position and secure funding to support its therapeutic development and approved products.
投資の参考になりましたか？